to a more functional understanding of cancer development [11, 12] . For example, Volinia et al. identified a set of universal microRNA signatures for solid cancers by a large-scale analysis on patients including lung, breast, stomach, prostate, colon, and pancreatic tumors [4] . Lu et al. found that with lower expression levels in tumors than in normals, microRNAs are unexpectedly rich in information about cancer [13] . In addition, microRNA and messenger RNA (mRNA) interactions remain incompletely understood in most cancers. Among solutions conducted to clarify these interactions, hundreds of putative microRNA targets have generally been calculated from nucleic acid sequence similarities and are provided in datasets (miRBase [14, 15] , miRanda [12] , PicTar [16, 17] , TarBase [18] and TargetScan [19] , reviewed by Bartel [20] ). However, sequence similarity alone, taking out of cellular context, leads to about 40% accuracy in microRNA target validations [21, 22] . Further, traditional biological characterization of microRNA targets is time consuming. Since expression arrays of microRNA and mRNA can be conducted over the same samples, there is an opportunity to reverse engineer regulatory mechanisms and to provide microRNA-target hypotheses. Though previous studies also identified regulatory bio-modules of specific human cancer by combining microRNA and mRNA expression profiles [23] [24] [25] [26] , their algorithms focus exclusively on linear inverse correlations [25, 26] and /or on previously predicted microRNA targets [24] [25] [26] [27] between two expression profiles that may not reveal other complex patterns of regulations that may appear paradoxical (such as co-expression). However, co-expression has been observed between intragenic microRNAs and a target gene, when this target happens to be the microRNA host gene [28] . Further, one can hypothesize downstream signaling that may paradoxically lead to co-expression of microRNAs with genes that aren't their immediate target. Of note, certain microRNAs have already been discovered to be either positively co-expressed with their target genes [29] , for example, miR-17-5p and its target E2F1 are positively coregulated by the proto-oncogene c-Myc [30] . Therefore, in this manuscript, we propose a novel unbiased computational strategy to derive microRNA-mRNA interactions biomodules that represent fundamental regulatory mechanism common to several cancers inclusive of inverse correlation and correlation patterns between microRNAs and mRNAs.
In bioinformatics, supervised machine learning techniques have been successfully used for classification and cancer diagnosis. So far, many supervised prediction metrics have been built to find the relation between gene expression and clinical conditions. The Support Vector Machine (SVM) is among the methods that have successful applications to the problems of cancer diagnosis [31] . The model of partial least squares (PLS) builds weighted linear combinations of genes that have maximal covariance with conditions of interest, but usually result in thousands of genes on microarray expression data. Assuming that only a few gene markers determine the classification of a genetic problem, the penalized logistic regression (PLR) is a technique that performs comparably to the SVM [32] and provides an estimation of the underlying class probabilities. PLR has been considered as a stand-alone for classification of microarray gene expression data with "small sample size, larger variances" [32, 33] and has been shown strongly predictive for clinical response in cancer as compared with the other above mentioned methods [33] . However to our knowledge, PLR has never been used over microRNA data before, nor for reverse engineering regulatory networks.
We hypothesized that we could identify in high throughput microRNA/mRNA biomodules common to different types of epithelial cancers that would also be associated to some fundamental biological mechanisms. We address the problem by re-analyzing the public data which includes 89 human epithelial samples including cancers and controls that have both mRNA and microRNA expression profiles [13] . Using PLR, we identify common microRNA-mRNA biomodules across epithelial cancers that best distinguishes them from normal epithelial tissues. Specifically, to reverse engineer the regulatory network consisting of microRNA and mRNA interactions, we assumed that microRNAs might act in concert with other regulatory processes to regulate gene's expression [34] without using any prior knowledge of microRNA target genes or any assumption on the inverse correlation of expression or co-regulation.
Methods

Datasets
Expression profiles of 217 microRNAs and 16,063 mRNAs for the same 89 epithelial samples were published by Lu et al. [13] (GSE2564) and Ramaswamy et al. [31] , respectively. They were among the very first paired samples of microRNA and mRNA expression, including 21 normals and 68 tumors. To generate the regulatory network, five microRNA gene target databases were downloaded and parsed to set up the comprehensive tables for human microRNA target genes. The five databases are miRBase v5 [14, 15] , miRanda version on July 2007 [12] , PicTar server version 4.0.24 [16, 17] , TarBase v4.0 [18] and TargetScan v3.1 [19] , which contain all together 1112 human microRNAs and 22084 predictive putative microRNA gene-targets. Additionally, Gene Ontology and PubMed databases were used to do evaluation in this study, using Bioconductor software [35] .
For the expression profiles, we did preprocessing and filtering on the downloaded data in two steps: (A) Preprocessing and preliminary filtering suggested by the author [13] : log2-transformation, keeping only those probes exceeding a measurement of 7.25 (on log2 scale) in one or more samples. This preprocessing and pre-filtering resulted in 195 microRNAs and 14546 mRNAs [13] . (B) Additional preprocessing steps to the microRNA and mRNA expres-sion profiles to concentrate on probe-sets that vary among different conditions. This variation filter [13, 31] involves the following steps: (a) setting a threshold using a ceiling of 1600 units and a floor of 20 units of expression measurement; (b) the maximum expression measurement was at least 5 fold greater than the minimum measurement, and (c) the maximum measurement was more than 500 greater than the minimum measurement. The filtering step resulted in 130 microRNAs and 6621 mRNAs. Finally, we performed "low-level fusion", that is, we combined expression profiles from two sources of microarrays before step-down analysis. This is different from high-level fusion (decision fusion) [36] in which microRNA-mRNA analysis are done in parallel rather than together. To allow expression levels to be comparable, we first scaled the combined data. Then we performed further supervised grouping.
Algorithm for sample classification and predictor-variable grouping
Penalized logical regression (PLR) algorithm has been proposed as a stand-alone for classification of microarray gene expression data with "small sample size, larger variances" [32, 33] and has been shown strongly predictive for clinical response in cancer as compared with the other above mentioned methods [33] . Let G = (1,g 1 ,…,g q ) be a group of q probe-sets,  be a vector of q parameters (each associated with one probe-set) that are trained to optimize (for example, to minimize the S() in Equation 3) the PLR model by a penalized maximum likelihood principle [37] . The classical logical model of PLR is defined as [38] :
Two implementations of PLR algorithms in this study were employed. (1) In the preliminary validation study comparing PLR usage in mRNA expression data alone, microRNA expression data alone and the combined profiles (step i in Figure 1 ), we applied three-fold cross validation using Bioconductor package MCRestimate and penalized maximum likelihood algorithm to estimate the classical PLR model, using the R package Design [39] . The PLR model was estimated from the data of training samples in cross-validation (CV), then in the subsequent tests within the CV, we performed a predict function for classification test data using the fitted model. The input data were the mRNA and/or microRNA expression together with classification annotation of test samples and the trained PLR model. The corresponding outputs here were predicted class labels of each test sample. (2) To identify the merged microRNA-mRNA biomodule that best classified normal epithelial samples from the combined set of epithelial cancers, we performed Supervised Grouping of Predictor Variables (pelora) method developed by Dettling et al. [37, 40] ,using the R package Supercluster.
In summary, the second implementation of PLR finds prioritized groups of variables (probes in a microarray) that can best explain the sample classes (cancer and normal in this study), employing the penalized log-likelihood function that is based on estimations of conditional class probabilities from PLR. As a result, the algorithm estimates conditional probabilities while focusing on similarities and intersections among predictor-variables in a supervised way [37, 40] . The assumption is as follows: let's assume there exist two groups of probe-sets, set A and set B , and two conditions of samples, e.g. tumor and normal. If it is indicative of cancer that the centroid of set A (C A ) is high while the centroid of set B (C B ) is low, then two such probe-sets and their contributions to the centroids can be understood as molecular signatures to gain insights into molecular regulation in cancer [40] . For details, let x be the observed measurement of expression of one probe-set, the centroid of a group of probe-sets G is given as:
using a discrete parameter  g ∈ {-1,1} that allows up-or down-regulated genes to contribute in the same group. In this way, this centroid approach can derive biomodules consisting of both up-and down-expressed probe-sets. This characteristic allows for unbiased observation of both the negative expression correlation between microRNA and target gene within the group [41] , and positive expression correlation between the microRNA and their host gene in the combined profiles [42] . Let  be a vector of parameters, λ be a variable parameter for penalization control, and P be a penalty matrix, the pelora [37, 40] measures the strength of a probe-set group G for distinguishing the n tumor/normal phenotypes (y 1 ,y 2 ,…,y n ) as:
where
is the estimated conditional class probability from penalized logical regression analysis. The pelora automatically scratches the starting probe-set for each group of probe-sets, then it incrementally increases the number of probe-sets in a group G i by adding or pruning one probe-set after the other, and recalculating after each change until it optimizes the sample classification in the training set. Once a group of probe-set and trained parameters are optimized as best, then pleora identifies the second best one. Therefore, by inputting a matrix of mRNA and/or microRNA expression with classification annotation of each samples, and setting the number of biomodules that should be searched to 10, while keeping other default parameter, we obtained 10 biomodules that PLR searched, each associated with their respective "rescaled penalty parameter ", and the fitted values of each biomodule. Step i: Comparing PLR usage in mRNA expression data, microRNA expression data and the combined profiles
We performed a three-fold stratified cross-validation [43, 44] as well as a re-randomization algorithms to assess and compare the predictive power of mRNA, microRNA and their combined expression profiles, where "three-fold" means random choosing the training-set to be two thirds of the samples, and "stratified" means the proportion of tumor tissues in the training set more or less the same as in the whole data set. Then, for the samples in the training-set, we employed penalized logistic regression (PLR) to train the classifier by modeling the probability of class membership. The resulting classifier model was then used to predict the samples in the remaining one-third test-set. Thus each run of the cross-validation yielded predictive class labels for the samples in the test-set. We iterated the above process 100 times and calculated the frequency of each sample correctly predicted in the test sets. The three-fold cross validation has been shown at least as conservative as the leave-one out method to provide robust estimates that are not over trained when using machine learning methods [45] [46] [47] .
After completing the above-mentioned cross-validations, we plotted the distribution of resulting predictions for the microRNA expression profiles alone, the gene expression profiles alone and also the combined microRNA-mRNA expression profiles. Then we further compared such three distributions of the validation results using F-test. The total accuracy, (TP+TN)/(TP+FP+TN+FN), of cross-validation was calculated, where TP (True positive) is the correctly classified cancer samples, FP (false positive) is the wrongly classified cancer samples, TN (True negative) is the correctly classified normal samples, and FN (false negative) is the wrongly classified normal samples. The 95% central confidence interval [48, 49] of the total accuracy for the population (89 samples) in this data was estimated using an online Bayesian calculator (http://www.causascientia.org/ math_stat/ProportionCI.html).
Step ii: Identification and the quantitative description of the discovered microRNA-mRNA biomodules and their interaction networks
The two kinds of filtered expression data were finally combined (6621 mRNAs and 130 microRNAs), log 10 transformed, and standardized. We used penalized regression model [50] to search prioritized microRNA-mRNA biomodules with good predictive potential based on this combined data, using Bioconductor package supclust [37, 40] .
First, we searched N = 1,...,10 leading biomodules from the combined microRNAs and mRNAs data. Second, we estimated the number of including biomodules that yielded the best prediction accuracy on the validated samples by cross-validation. We iteratively ran a three-fold cross validation 100 times, using Bioconductor package MCRestimate. A PLR model of the learning set was obtained for each number of including group n∈ N, and then applied to the test set while the predicted labels were compared with the true labels. The fraction of misclassified individuals was estimated for each number of including biomodules. For comparison, we also did the same estimation for mRNA and microRNA data, respectively. The optimal number of included biomodules is the n* that achieved the lowest misclassification. We then merged the n* leading biomodules into a merged epithelial cancer biomodule for further validation.
We summarized the genes and microRNAs involved in the merged epithelial cancer biomodule as comprehensive tables of human microRNA target genes. To describe the regulatory network, we made use of shapes and colors: circle (gene), box (microRNA), pink node (averagely up-regulated gene and/or microRNA in cancer), blue node (averagely down-regulated gene and/or microRNA in cancer), and orange node (tissue-specific expressed gene target of down-expressed microRNAs).
Step iii: Expression patterns of the microRNA-mRNA biomodules classify epithelial cancers and normal samples across all 11 Types of Tissues The 10 microRNAs and 98 genes identified in the microRNA-mRNA biomodule and all samples were hierarchically clustered using complete Mutual Information distance of the expression levels, (Bioconductor package Biodist). We also observed the expression patterns of microRNAs and genes in each prioritized biomodule, to see whether individual biomodules could classify epithelial cancers and normal samples across 11 types of tissue.
Step iv: Gene Ontology enrichment Validation of gene ontology enrichment of the biological processes was conducted in the genes of the epithelial cancer biomodule in order to biologically characterize the biomodule. We used the Bioconductor package GOstats [51] to estimate the Biological Processes (BP) enriched in genes of six microRNA-mRNA biomodules (version 2.6.0 based on Hu6800.db v2.2.0, hu35ksuba.db v2.2.0 and GO.db v2.2.0, parameters p-value ≤ 0.01, gene count > 2). This package GOstats reports a standard hypergeometric p-value to access whether the number of selected genes among the genes in an annotated array associated with a GO term is larger than expected [51] , and it is a standard tool to evaluate the overrepresentation of GO terms among a given gene set and has been successfully implemented [52] . As each GO term is considered independently in GOstat, the review of the enrichment was conducted with the understanding that if related or possibly redundant GO terms were found to be enriched, the nature of this relationship could depend on the intrinsic annotations rather than the structure of GO (e.g. redundant annotations of genes to related GO terms). Additionally, because the raw data contains two different mRNA platforms, we also used an old version of Bioconductor package Compdiagtools (version in April 2007) to access the BP from whole human genome (Gene Ontology Built:
15-Mar-2006) enriched in these 98 genes identified in biomodules (parameters: p ≤ 0.05, gene count ≥ 2).
Step v: Evaluation of enrichment of inversely correlated microRNA-mRNA pairs in the Biomodules computed by expression among microRNA-target pairs predicted from nucleotide sequences microRNA target Enrichment of microRNA targets in the network was evaluated using Fisher exact test to estimate possibility of drawing the intersection of biomodule observed inversely correlated microRNA-mNRA pairs from all putative microRNA-target pairs based on sequence similarities that contained in five databases (miRBase v5 [14, 15] , miRanda version on July 2007 [12] , PicTar server version 4.0.24 [16, 17] , TarBase v4.0 [18] and TargetScan v3.1 [19] ). This study was performed on the expression profiles of 217 microRNAs and 16063 genes, about which there were 121755 putative microRNA-target pairs among all possible 3485671 pairs. We then counted the six biomodules identified inversely correlated microRNA-mRNA pairs and the intersection number of identified inversely correlated pairs among putative target pairs to calculate the p-value.
We looked into the significance of differential expression for each gene and microRNA that acts together to best classify epithelial tumors versus normal tissues. To estimate the individually false positives rate when expression changes were significant [53] , we calculated the q-value [53] of fold-change equivalent measures on the log-transformed expression levels using Bioconductor package twilight [54] . The Entrez Gene IDs for mRNAs were mapped from probe sets using package hu6800 version 2.2.0, and package hu35ksuba version 2.2.0 in R.
Step vi: Systematic review of literature to identify the relevance of the gene patterns observed in the biomodules
We assessed the significance of the co-occurrence for every pair of two terms in which one was a microRNA or gene symbol and the other was a cancer type, to see the association between cancer and gene-or microRNAs in the identified biomodule. Similarly, using the online literature mining tool PubMatrix [55] , we searched the PubMed indexed publications and counted the number of abstracts containing the symbol of the identified microRNA or gene and epithelial cancer type, also the number of co-occurrence of pair of terms. The total number of indexed publication was derived from the PubMed online review tool. Subsequently, Fisher's exact test was used to estimate the significance to co-occurrence. Let N be the totally records in PubMed, n 2 be the number of abstracts containing a symbol of microRNA or gene, n 3 be the number of abstracts about cancer, and n 1 be the number of abstract mentioning both, we got the contingency table (Table 1) for each symbol and cancer. Then one-side Fisher's exact test was applied to evaluate the significance of co-occurrence. A threshold of unadjusted p < 0.05 was set for to indicate a true positive result in this evaluation.
Results
2.1
Preliminary validation study comparing PLR usage in mRNA expression data alone, microRNA expression data alone and the combined Results
In order to demonstrate the increased statistical power of classification using joint microRNA and mRNA expressions, we compared the classification accuracy for micro-RNA, mRNA, and the expression profiles of both kinds of microarrays on the same 89 epithelial samples, representing 11 types of human tumor (colon, pancreas, kidney, bladder, prostate, ovary, uterus, lung, mesothelioma, melanoma, and breast cancer) [13] .
To estimate the total accuracy of expression profiles, we repeatedly (n=100) performed 3-fold [43, 44] stratified cross-validation, using standard PLR as the classifier to predict cancer from normal samples (details are given in section methods). The meta-analysis of both mRNA and microRNA expression profiles resulted in a higher accuracy with smaller variance (Figure 2) . The differences between the predictions from individual mRNA or microRNA and the predictions from integrated data are significant (F-test = 56.27, p = 1×10 -10 ). Our results suggest that there are groups of non-coding and coding genes that work together with respect to the classification (total accuracy = 93.3%; 95% confidence intervals: 86%-97%) of cancer tissue vs. normal tissue for the 11 types of epithelial tissues.
Figure 2
Standard box-and-whisker plots of the error rate of repeated cross-validation on mRNA profiles, microRNA profiles and on the combined profiles. Each box presents the smallest observation, lower quartile, median, upper quartile and the largest observation, the whiskers are the lines that extend to a maximum of 1.5 times of the inter-quartile range (the range of the middle two quartiles) excluding outlines, and the circles represent the outliers. The y-axis gives the probability of samples to be wrongly predicted. The dashed line is the normal (lower) prevalence of the samples.
To identify the contribution of each specific epithelial tissue to the accuracy, we further counted the classification accuracy in each type of tissue ( Table 2 ). The results indi Table 2 The population size and classification total accuracy in percentage (%) from 3-fold cross-validation for each type of cancer and as a whole in this study. The last row of this table lists the sample populations for each tissue and as a whole. The last three columns list the total accuracy for all types of cancer as a whole and the corresponding confidence intervals (CI). CI: 95% confidence interval calculated by a Bayesian calculator [48, 49] cate that, with the exception of colon cancer, no specific tissue type alters the total accuracy of classification of the combined expression profile, implying that there are common expression patterns among distinct kinds of epithelial cancers in the context of expression levels of both mRNA and microRNA. The lower accuracy of cancer-vs-normal diagnosis of colon sample in this dataset suggests a tissue-specific expression pattern among these colon samples because the dataset contains eleven different anatomical locations of epithelial tissues. Interestingly, for each tissue type, the analysis of the combined microRNA-mRNA expression resulted in a relatively higher accuracy than either the microRNA or the mRNA expression profiles conducted alone did.
Identification and the quantitative description of the discovered biomodules and their interaction networks
We previously confirmed that combining the expression profiles of mRNAs and microRNAs can lead to higher classification power. In order to discover the common group of mRNA and microRNAs interactions that best classified epithelial cancers separately from normal tissue, regardless of the specific cancer or anatomical location, we employed PLR on the whole combined microRNA and mRNA expression profiles to generate ten prioritized groups (biomodule candidates). To answer the question of how many biomodules should be optimal to best classify, we conducted a prediction-based statistical inference on the datasets [56] . Six microRNA-mRNA biomodules contributed to the lowest 95% quintile of the error-rate on the combined data (Figure 3) . In particular, the error-rate of microRNA data stably decreased when n < 3, while the combined data showed an increased tendency of error-rate when n > 6. Our results confirm the six microRNA-mRNA biomodules that perform commonly in several types of human epithelial tumor. Thus our further investigation and discussion will focus on the leading six groups which are referred as "expression microRNA-mRNA biomodule". The biomodules contain 10 distinct microRNAs and 98 distinct genes, (3 microRNAs and 24 genes, 3 microRNAs and 22 genes, 4 microRNAs and 21 genes, 5 microRNAs and 24 genes, 1 microRNAs and 6 genes, 1 microRNAs and 19 genes, respectively). Two microRNAs and 11 mRNAs were involved in multiple microRNA-mRNA biomodules, such as miR-30e, miR-15a, ABO, METTL7A, CFD, IRAK1, PTMS, MED6, etc (Suppl. Table 1) . A two-dimensional projection of tumor (red 1) and normal (black 0) samples into the space of the expression level of the first biomodule (x axis) and second biomodule (y axis) separates the samples of tumor and the normal tissue (Figure 4) . Moreover, the combined analysis of microRNA and mRNA (leftmost projection of Figure 4 ) yields larger between-cluster distance than within-cluster distances.
Expression patterns of the microRNA-mRNA biomodules that classify epithelial cancers and normal samples across 11 types of tissues
The genes and/or microRNAs within a biomodule should have the biggest within-module correlation and biggest central distance between cancer and normal sample groups. The mutual information (MI) has been used as a measurement between two genes related to their degree of independence [57] . The hypothesis here is that a higher measurement of mutual information observed between the expression of two genes and/or microRNAs indicates a closer biological relationship. Therefore, we used MI to validate the expression pattern of the combined six biomodules identified by PLR algorithm as best predictors (lowest prediction error using cross-validation in Figure  2 ). Figure 5 shows that the jointed six modules can distinguish epithelial cancer from normal tissue samples using MI measurements. We also found high mutual information between the microRNAs and/or genes in the six biomodules (data not shown).
Gene Ontology (GO) enrichment of the genes associated with these biomodules
To further understand the biological mechanism underling the identified merged microRNA-mRNA biomodule, we conducted a Gene Ontology enrichment of the biological processes and also reviewed the literature for the genes involved in the merged microRNA-mRNA biomodule. Table  3 gives 7 Biological Process terms defined by Gene Ontology (Built: 15-Mar-2006), which are significantly overrepresented within the 98 genes based on running hypergeometric tests for each GO term of two Affymetrix chips (hu35ksuba and hu6800). Many of these biological processes are known to be involved in oncogenesis (e.g. DNA replication, growth, nucleic acid metabolism, etc.). The hypergeometric tests evaluate the likelihood that the corresponding number of annotations is occurring in a random list of genes of the same size using R CompdiagTools package. PTMS [58] , MCMC7 [59, 60] , TK1, and NFIB are the genes important for DNA replication (hypergeometric p-value is 0.007). Higher expression levels of PTMS [61] , TK1 [62] , and MCM7 [60] in epithelial carcinoma cells than in normal cells has been reported. The over-expression of IRAK1 and under-expression of TGFBR2 in tumor cells have been previously reported as well [63, 64] . The genes enriched in protein amino acid dephosphorylation are all famous tumor suppressors or oncogenes. Both DUSP16 [65] , positively, and TGFBR2 [66, 67] , negatively, are involved in the MAPK signaling pathway. CDC25B phosphatase, as a kind of cyclin-dependent kinase activator, Figure 5 The heatmap of log-transformed expression levels of microRNAs-genes biomodules across 89 epithelial samples. The 10 microRNAs (symbols in red) and 98 genes and all samples are ordered by a hierarchical cluster agglomerated on complete Mutual Information distance of the expression levels, using Bioconductor package Biodist. The two black vertical lines range the normal samples that were clustered together. The annotation of the 89 sample are "tumor_T" or "tumor_N" (e.g. normal kidney tissue is Kid-N); Kid=kidney, BLDR=bladder, PAN=pancreas, BRST=breast, BLDR=bladder, UT=uterus, MELA= melanoma, MESO=mesothelioma, PROST=prostate.
plays a key role in cell-cycle progression and the MAPK signaling pathway with positive expression [68] . In contrast, each biomodule individually did not have sufficient genes to achieve statistic power or to identify meaningful non-trivial processes (Suppl. Table 2 ).
Evaluation 1 -Enrichment of microRNA targets among inversely correlated microRNA-mRNA pairs
The PLR identified six microRNA-mRNA biomodules comprising 10 microRNAs and 98 mRNAs. The average expressions of every one of the 10 microRNAs were down-regulated in the epithelial cancer group as compared with the normal tissue group, while 59 out of 98 mRNAs were up-regulated. There were another 39 mRNAs in this biomodule that were down-regulated in cancer. Five databases of microRNA target predictions based on sequences were used: miRBase v5 [14, 15] , miRanda version on July 2007 [12] , PicTar server version 4.0.24 [16, 17] , TarBase v4.0 [18] and TargetScan v3.1 [19] , and they were used to ascribe relationships between genes and microRNAs within each biomodule clusters to generate the network (shown in Figure 6 ) comprising 35 microRNA-targets relationships. Among the biomodules, 208 distinct pairs of inversely correlated microRNA-mRNA were found, of which 29 were also found in the five putative microRNA target databases based on sequence similarities that contain 121755 distinct pairs of microRNA-target. All together, 217 microRNAs and 16063 genes were studied, with a potential for 3485671 microRNA-mRNA interactions. Therefore, the Fisher's exact test showed a significant enrichment (p = 3×10 -10 , odds ratio = 4.5) of observed microRNA-mRNA inverse correlations pairs in the six biomodules, corroborating the validity of the proposed approach.
In some cases, the microRNA target was only up-regulated in some subset of epithelial cancers (tissue-specific inverse correlation with the microRNA). To address this question, we further measured the tissue-specific log-transformed group distance of expression for every microRNA and gene in the six biomodules (Suppl. Table 3) . Eight putative target genes were down-regulated in the epithelial cancers group as compared with the normal tissue group and up-regulated in a specific cancer tissue as compared with the expression in the comparable normal tissue (Suppl. Table 3 ). And three microRNAs (has-miR-143, -193 and has-let-7b) were down-regulated in every cancers except in colon cancer; while has-miR-1 was down-regulated in all cancers except in pancreas cancer. Besides, there are four down-regulated putative target genes (SPCS1, FABP4, PDK4 and IHPK2) of one of the 10 microRNAs in the combined biomodules. Note that our method didn't make any assumptions on the mechanism of correlation or inverse correlation between microRNAs and genes expressions in the same biomodule; therefore it identified co-expression as well inverse co-expression patterns. As described in the background, correlation of microRNA and mRNA expression may be attributed to mechanisms such as genes hosting an intragenic microRNA correlated with the expression of their intragenic microRNA [42] , or target genes regulated by other mechanism such as transcriptional factor [29, 34, 69] 
Figure 6
Regulatory network consisting of microRNAs and their putative gene targets in the six combined microRNA-mRNA biomodules. Circle (gene), box (microRNA), pink node (up-regulated gene or microRNA in epithelial cancer), blue node (down-regulated gene or RNA in epithelial cancer), and orange node (tissue-specific up-regulation of the gene target associated with the down-expressed microRNAs as described in Suppl. Table 3 ). It includes 9 out of 10 down-regulated microRNAs and their predicted target genes (n=26) summarized from five public databases observed among the 98 genes of the six combined biomodules. All the identified microRNAs have already been reported associated with human cancer, except miR-33. The known tumor-suppressive microRNAs are miR-30e in breast, head and neck, and lung cancer [70] , miR-193a and miR-338 in oral squamous cell carcinoma [71] , miR-15a in prostate cancer [72] , miR-130a in the drug-resistant cell lines of ovarian cancer [73] , miR-136 in leukemia [74] , miR-143 in cervical cancer [75] , colorectal cancer [76, 77] and nasopharyngeal carcinoma [78] , miR-1 in lung cancer [79] and hepatocellular cancer [80] , let-7b in the poor-prognostic ovarian carcinoma [81] , colon cancer [82] , lung cancer [83] and melanoma [84] . Our result suggests that the new candidate miR-33 may also function as growth suppressors in human epithelial cancer cells.
We found that apoptosis related microRNAs (miR-338, miR-193a) and genes (BCL2L13, PDCD2, IRAK1, IHPK2, INHBA, BFAR and MCM7), as well as genes involved in cell division cycle pathway (RAD1, PTMS, INHBA and CDC25B) and DNA replication (NFIB, PTMS, MCM7 and TK1), are promising markers for diagnosis of human epithelial cancer. Other known tumor markers that we found include IRAK1, TGFBR2, DUSP16, and CDC25B. Some tumor suppressor genes such as PDCD2 also showed consistent down-regulation in all human tumors derived from epithelial tissues. Our most interesting findings are that many genes in the group of diagnostic markers are the expected targets of the identified microRNAs. Although computational prediction of microRNA targets requires experimental validation, this observation further reveals the complicated relationship between microRNA and genes in tumors [85] . We suggest that combining expression profiling of microRNA with mRNA is a promising strategy to predict the risk of epithelial tumors.
We also summarized and did basic statistics on the genes and microRNAs in these microRNA-mRNA biomodules for further possible investigation. All 10 microRNAs and 75% of the identified genes show strongly significant changes (q < 0.05 [54] ), when we did fold-change equivalent measures on the log-transformed expression levels [53] (Suppl. Table  1 ). Note that since the biological events are not independent, we cannot assess the performance by individual genes. Individually, some of the identified diagnostic signatures have mediocre identification power but if joined together, they may have good classification power.
Discussion
In this paper, we described an integrated analysis of expression levels of protein-coding transcripts and non-coding transcripts. We used modern classification and evaluation methods based on penalized logistic regression (PLR) and found that the combining analysis of mRNA and microRNA expression profiles resulted in the lowest rate of misclassification. Furthermore, these biomodules found by PLR are sorted according to their variances in descending order. We then identified and investigated a group of six leading microRNA-mRNA biomodules whose collective expression was strongly associated with epithelial cancers from different originals as compare with their corresponding normal tissues. The first, second and third biomodules could individually distinguish cancers from controls, suggesting the diversity of distinct biomodules involved in distinct mechanisms associated with epithelial cancers.
Tumorigenesis is a multi-step process in which cancer cells acquire characteristics such as self-sufficiency in growth, evasion of apoptosis, insensitivity to growth inhibitory signals, limitless replicative potential, and so on. Early detection of cancer is the key for the application of successful therapies. MicroRNAs have recently been identified as a new class of genes with tumor suppressor and oncogenic functions. More researchers are considering the advances of microRNA expression profiling and discussing their potential in cancer diagnostics and prevention. It is known that most microRNAs are controlled by developmental or tissue-specific signaling and that there are tissue special regulatory microRNA and gene expression patterns. However, our study shows that some microRNAs are consistently under-expressed in 11 different types of epithelial tumors compared with normal tissues, strongly suggesting that there are common microRNA regulatory patterns occurring in distinct types of epithelial cancers from distinct anatomical origins. The regulatory network of the identified microRNAgene biomodules include the co-expression and inverse coexpression patterns within a biomodule, implying the complexity of regulatory mechanisms beyond the direct micro-RNA target, such as a host microRNA gene co-expressed with its intragenic microRNA, more complex interactions mediated via signaling and transcriptional activity [30, 34, 42] , or a microRNA and gene activated by the same regulator [30] .
In contrast to the algorithm of decision fusion by Wang et al. using the same datasets, our study is superior in two points. Wang's "high level decision fusion" consists of analyzing separately microRNAs and mRNAs. (1) Our proposed "low-level data fusion" method is more suitable for mining the oncogenic microRNAs and their regulation of gene expression. We combined and scaled the two sources of expression profiles to produce a new meta-data. Moreover, the null hypothesis of the method adopted by Wang et al. was that the expression levels for the variables were the same for normal tissues and tumors [36] , however a large fraction of the world of known microRNAs were downexpressed in cancer [6, 86] . (2) Our method is good for feature selection because it is based on the PLR algorithm which is designed for searching small functional groups of genes/microRNAs that act together and whose collective expression is strongly associated with response conditions. PLR is also superior to classification with state-of-the-art methods based on single genes [33] . Therefore, our method can identify the signature from complete mRNA and microRNA expression changes which might be ignored in an individual data source.
Compared with other studies that calculate the biomodules of microRNA-mRNA by combining both expression profiles, our study is different in two ways: (1) The proposed unbiased and genome-wide method identifies microRNA-mRNA biomodules inclusive of both correlations an inverse correlations between microRNA-mRNA, while previous methods only addressed the latter (biased) and generally also used previous knowledge from microRNA target databases to reduce the number of comparisons (not genome-wide) [24] [25] [26] [27] . (2) The proposed method is an alternative to bi-clustering which results in biomodules made of dys-regulated microRNA and mRNAs whose collective expression are strongly associated with cancer conditions, because the algorithm balances between the within group co-expression and between group distance. In contrast, previous methods based on negative linear correlation between microRNA and mRNA expression profiles did not distinguish cancer and normal conditions [24, 26] or distinguished them depending on arbitrary threshold of differential expression either [25] .
Future studies of microRNA-mRNA biomodules common to multiple cancers will be: (1) the development of robust biomodules by generating a subset of robust genes and microRNA within biomodules using cross-validations or other studies; and (2) conducting biological validations on some uncharacterized mechanisms that we have predicted. (3) In addition, the open question in our identified microRNA-mRNA biomodules is that some microRNAs are co-expressed with their putative target genes in this dataset. We should add additional databases, such as transfac, or other approaches to further characterize the putative mechanism involved in this otherwise paradoxical result, particularly when this correlation is observed between a microRNA and its putative target gene. It either challenges the disease specific roles of microRNA on its target genes [87] , or challenges the prediction precision of putative target genes in those databases. In fact, neuronal-enriched microRNAs have been discovered to be either positively or negatively co-expressed with their target genes [29] . Therefore, besides the repressive effect on target expression, microRNAs might act in concert with other regulatory processes [42] to regulatory target gene expression [29, 34, 69] . Therefore the combination of genome-wide microRNA and mRNA expression provides increasing information to further understanding of the multiple levels of dys-regulatory network in human cancer by integrating microRNA into regulatory networks [88] .
Conclusions
Current approaches to derive microRNA-mRNA interactions from their respective expression profiles over paired tissue samples are generally focused on statistical associations of their expressions and in many cases, assume an inverse correlation to the interaction. Different from others, we focused on coordinating mRNA and microRNA expressions together by rescaling their normalized values and treating them as probe-sets of a common pool. We then developed and evaluated a novel comprehensive method to systematically identify, on a genome scale, pan-expression biomodules commonly to distinct cancers of the same tissues. These pan-expression biomodules are enriched in genes and microRNAs that have previously been identified in epithelial cancers, using literature review. Since micro-RNA can sometimes induce mRNA degradation with their complementary mRNA molecules, we confirmed that the biomodules were significantly enriched in microRNAs associated with their inversely correlated putative gene targets. Additionally, we have demonstrated that the pan-expression biomodules are robust classifiers of cancer vs. normal conditions. Taken together, these observations support the internal validity and biological consistency of the pan-expression biomodules in epithelial cancers. Further, the regulatory network of the identified microRNAs and corresponding genes in these biomodules may contribute to the understanding of the complexity of microRNA-mRNA interactions by providing unbiased synthetic models and hypothesis generation to cancer biologists. 
